- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03130699
Dulce Digital-Me: An Adaptive mHealth Intervention for Underserved Hispanics With Diabetes (DD-Me)
November 18, 2021 updated by: Athena Philis-Tsimikas, Scripps Whittier Diabetes Institute
This study will compare Dulce Digital (i.e., the investigators' proven-effective combination of "one-size-fits-all" educational text messages and nurse monitoring of patient-transmitted blood glucose values) and Dulce Digital-Me (DD-Me), an adaptive/dynamic mHealth (mobile health) intervention that is tailored to individuals' needs and behavioral progress, in improving diabetes clinical control, adherence, and patient-provider communication in Hispanics - an at-risk, understudied population that experiences disparities in diabetes prevalence and outcomes.
These striking disparities in the growing and aging US Hispanic population have taxed the US healthcare system, while significantly reducing quantity and quality of life for millions of individuals.
By offering an innovative, scalable, and sustainable approach that seamlessly integrates several mHealth technologies into existing primary care team processes to improve the health of Hispanics (and eventually, other at-risk, underserved groups), DD-Me has strong potential to significantly impact public health.
Study Overview
Status
Completed
Conditions
Detailed Description
Individuals of low socioeconomic (SES) and ethnic minority status, including Hispanics, the largest U.S. ethnic minority group, are disproportionately affected by diabetes.
Poor healthcare access and cultural barriers prevent optimal care, adherence, and clinical benefit, thus placing Hispanics at high risk for costly diabetes complications.
The investigators' established academic-healthcare-community partnership has unique experience in developing and testing innovative, cost-effective, and sustainable chronic care interventions to reduce disparities and improve health in underserved communities.
The investigators recently developed Dulce Digital (i.e., "one-size-fits-all" educational text messages, with nurse monitoring of patient-transmitted blood glucose values), which improved glycemic control across 6 months, relative to usual care in a recent randomized controlled trial (RCT) of N=126 Hispanic patients with poorly controlled type 2 diabetes (T2DM).
The process evaluation for this trial indicated that Dulce Digital was both feasible and acceptable from patient and provider perspectives; however, patients expressed a preference for a more individualized intervention, and providers requested an even greater focus on health behavior change.
Thus, the proposed RCT will examine the comparative effectiveness of Dulce Digital versus "Dulce Digital-Me" (DD-Me) in N=414 Hispanic adults of low SES with poorly controlled T2DM from Neighborhood Healthcare, a San Diego Federally-Qualified Health Center.
Guided by patient and provider feedback, DD-Me includes Dulce Digital components plus personalized goal-setting and feedback that is responsive to the individual's needs and preferences.
The DD-Me adaptive feedback component will be informed by the Resources and Support for Self-Management Model and Operant Conditioning Theory, and based on the individual's progress on intermediate behavioral targets (i.e., medication adherence assessed by wireless sensor; brief mobile phone-based assessments of diet, physical activity, stress).
Feedback will be delivered via algorithm-driven automated messaging in 50% of DD-Me participants and by the care team medical assistant in the remaining half to determine the feasibility and acceptability (given the purported cultural relevance of interpersonal relationships in the Hispanic culture), and the comparative effectiveness and cost of each delivery method.
Changes in indicators of diabetes clinical control [i.e., glycosylated hemoglobin (HbA1c) low density lipoprotein cholesterol (LDL-C), systolic blood pressure (SBP)], patient-provider communication, and patient adherence (i.e., to medication and other diabetes self-management behaviors) will be evaluated across twelve months.
Thorough process and cost-effectiveness analyses will evaluate the scalability and sustainability potential of DD-Me.
This comparative evaluation of two mHealth approaches will elucidate how technology can be integrated most effectively and efficiently within existing nurse-led chronic care approaches to meet the complex needs of underserved individuals with poorly controlled T2DM.
Study Type
Interventional
Enrollment (Actual)
310
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Chula Vista, California, United States, 91910
- Scripps Mercy Chula Vista
-
La Jolla, California, United States, 92037
- Scripps Whittier Diabetes Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Self-identified Hispanic/Latino
- 18 years or older
- Registered patient of a Neighborhood Healthcare Clinic
- Diagnosed with T2DM (Type 2 Diabetes Mellitus)
- HbA1c ≥ 8.0% and/or SBP ≥ 160 mmHg, and/or LDL-C ≥ 100 mg/dL in the last 30 days
Exclusion Criteria:
- Severe illness precluding regular clinic visits
- Pregnant or lactating
- Type 1 or gestational diabetes
- Lack of minimal literacy
- Plans to relocate
- Severe auditory or visual problems
- Primary language other than Spanish or English
- Unwilling to carry a mobile phone
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dulce Digital
The first of the three arms of the parallel design: The group of participants randomly assigned to this arm of the study receives one-size-fits-all educational text messages, with patient monitoring and transmission of blood glucose values.
|
One-size-fits-all educational text messages, with patient monitoring and transmission of blood glucose values.
|
Experimental: Dulce Digital-Me (Automated Delivery)
The second of the three arms of the parallel design: The group of participants randomly assigned to this arm of the study receives educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered via automated algorithm-driven messaging, incorporated into existing primary care team processes.
|
Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered via automated algorithm-driven messaging, incorporated into existing primary care team processes.
|
Experimental: Dulce Digital-Me (Medical Assistant)
The third of the three arms of the parallel design: The group of participants randomly assigned to this arm of the study receives educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered by Medical Assistants, incorporated into existing primary care team processes.
|
Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered by Medical Assistants, incorporated into existing primary care team processes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Systolic blood pressure (SBP); mmHg units
Time Frame: 12 months
|
12 months
|
Glycosylated Hemoglobin (HbA1c); % units
Time Frame: 12 months
|
12 months
|
Low-density lipoprotein-cholesterol (LDL-C); mg/dL units
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Summary of Diabetes Self-Care Activities (SDSCA) - patient-reported outcome
Time Frame: 12 months
|
12 months
|
Patient Activation Measure (PAM) - patient-reported outcome
Time Frame: 12 months
|
12 months
|
Patient Assessment of Chronic Illness Care (PACIC) - patient-reported outcome
Time Frame: 12 months
|
12 months
|
Chronic Illness Resources Survey (CIRS) - patient-reported outcome
Time Frame: 12 months
|
12 months
|
Adherence to Refills and Medications Scale (ARMS) - patient-reported outcome
Time Frame: 12 months
|
12 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cost Effectiveness using the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model
Time Frame: 12 months
|
12 months
|
Pay for Performance (P4P) Clinical Metrics
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Linda Gallo, PhD, San Diego State University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 22, 2017
Primary Completion (Actual)
August 14, 2021
Study Completion (Actual)
August 14, 2021
Study Registration Dates
First Submitted
April 24, 2017
First Submitted That Met QC Criteria
April 24, 2017
First Posted (Actual)
April 26, 2017
Study Record Updates
Last Update Posted (Actual)
November 22, 2021
Last Update Submitted That Met QC Criteria
November 18, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R01DK112322-01A1 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Dulce Digital
-
Scripps Whittier Diabetes InstituteNational Center for Advancing Translational Sciences (NCATS)Recruiting
-
Scripps Whittier Diabetes InstituteRecruiting
-
Scripps Whittier Diabetes InstituteRecruitingDiabetes Type 2United States
-
Scripps Whittier Diabetes InstituteNot yet recruiting
-
Boston Medical CenterCenter for the Study of Social PolicyCompletedChild Abuse | Parenting | Child Development | Child Rearing | Child NeglectUnited States
-
Scripps Whittier Diabetes InstituteNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); San... and other collaboratorsCompleted
-
Scripps Whittier Diabetes InstituteCompleted
-
South London and Maudsley NHS Foundation TrustUnknownFirst Episode PsychosisUnited Kingdom
-
Chang Gung Memorial HospitalCompletedStroke | Cerebrovascular Disorders | Central Nervous System DiseasesTaiwan
-
Swing Therapeutics, Inc.CompletedFibromyalgiaUnited States